Baker David Charles reported grant involving 3,935 derivative units of GRI Bio, Inc. at $0.00 for $0 on Nov 4, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Nov 13, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
3,935Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
3,935Direct
Trade date
Nov 4, 2026Grant
Filed
Nov 13, 2026, 5:18 PM ET9-day reporting delay
Accession
0001844060-26-000003Code A · Transaction 401069
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
delayed filingThe filing was reported 9 calendar days after the transaction date.

GRI price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
GRI · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 20, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: The stock option vests in 4 equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant.